Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · HERON THERAPEUTICS, INC. /DE/ (HRTX)

Heron Therapeutics signs multi-product US license deal with Long Grove Pharmaceuticals

Neutral Impact 3 of 5 product/contract Written later

Heron Therapeutics entered a multi-product Development and License Agreement with Long Grove Pharmaceuticals and Capstone Development Services on September 23, 2026. The deal gives Heron an exclusive, sublicensable license to import, distribute, sell and market certain products in the United States and its territories, plus a non-exclusive manufacturing license worldwide for sales in that territory. The filing does not disclose any upfront payment, milestone amounts or royalty rates, so its financial size for shareholders cannot be determined from this document.

Key points

  • Agreement dated September 23, 2026 with Long Grove Pharmaceuticals, LLC; Capstone Development Services Company, LLC is a party solely for exclusivity covenants and backstop obligations
  • Heron must pay Long Grove regulatory milestones, sales-based milestones and royalties, and be reimbursed for certain expenses; amounts are not stated
  • Initial term of 10 years from first commercial sale, with automatic 2-year renewals; either party may terminate on certain customary conditions
  • Full agreement to be filed as an exhibit to the Form 10-Q for the quarter ending September 30, 2026

The filing

CompanyHERON THERAPEUTICS, INC. /DE/ (HRTX)
Form8-K, current report
Filed with the SECSep 29, 2026, 5:00 PM ET
Accession number0001193125-26-407728

Items reported: 1.01 Material Definitive Agreement

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:51 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 29, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.